SWOG clinical trial number
S2114

A Randomized Phase II trial of consolidation therapy following CD19 CAR T-cell treatment for Relapsed/Refractory Diffuse Large B-cell Lymphoma or Grade IIIB Follicular Lymphoma

35% Accrual
Accrual
35%
Open
Phase
35% Accrual
Accrual
35%
Abbreviated Title
Ph II consolidation therapy following CD19 CAR-T for R/R DLBCL or Gr III FL
Status Notes
Activated: Effective Thursday, February 23, 2023 at 12:00 PM Pacific Time
Activated
02/23/2023
Participants
ALL NATIONAL CLINICAL TRIALS NETWORK MEMBERS

Research committees

Lymphoma

Treatment

Mosunetuzumab Polatuzumab vedotin

Patient Study Materials

Patient Clinical Trial Summary
Download PDF of Patient Clinical Trial Summary

Other Study Materials

Reports & Approvals

Trial Locations

Other Clinical Trials

S2308
SWOG Clinical Trial Number

Randomized Phase III Study of Mosunetuzumab vs. Rituximab for Low Tumor Burden Follicular Lymphoma

Research Committee(s)
Lymphoma
Activated
08/01/2024
17% Accrual
Accrual
17%
Open
Phase
S2207
SWOG Clinical Trial Number

Randomized Phase II Study of the Addition of Targeted Therapeutic Agents to Tafasitamab-Based Therapy in Non-Transplant-Eligible Patients with Relapse/Refractory Large B-Cell Lymphoma

Research Committee(s)
Lymphoma
Activated
06/30/2023
12% Accrual
Accrual
12%
Open
Phase
CTSU/AHOD2131
SWOG Clinical Trial Number

A Randomized Phase 3 Interim Response Adapted Trial Comparing Standard Therapy with Immuno-oncology Therapy for Children and Adults with Newly Diagnosed Stage I and II Classic Hodgkin Lymphoma

Research Committee(s)
Lymphoma
Immunomolecular Therapeutics
Activated
04/28/2023
Open
Phase